Boston Scientific beats by $0.01, beats on revs; guides Q4 EPS in-line (raises FY15 outlook)
- Reports Q3 (Sep) earnings of $0.24 per share, excluding non-recurring items, $0.01 better than the Capital IQ Consensus of $0.23; revenues rose 2.3% year/year to $1.89 bln vs the $1.86 bln Capital IQ Consensus; operational rev +9% with organic +5%.
- Co issues in-line guidance for Q4, sees EPS of $0.23-0.25, excluding non-recurring items, vs. $0.25 Capital IQ Consensus Estimate; sees Q4 revs of $1.97-2.01 bln vs. $1.98 bln Capital IQ Consensus Estimate.
- Raises FY15 outlook.